Professor Qing Cao’s Team: FA-ME Improves Diagnostic Efficacy for Children with Meningitis/Encephalitis | ESCMID Global 2024

Professor Qing Cao’s Team: FA-ME Improves Diagnostic Efficacy for Children with Meningitis/Encephalitis | ESCMID Global 2024

Despite ongoing developments in antimicrobial drugs and vaccines, the diagnosis of bacterial meningitis and viral encephalitis remains challenging due to their varied clinical presentations and is closely associated with high mortality rates. Traditional diagnostic methods have limitations, such as low positivity rates and lengthy processing times for cerebrospinal fluid (CSF) cultures, making early clinical diagnosis and treatment particularly difficult, especially in pediatric patients. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study by Professor Qing Cao's team from Shanghai Children's Medical Center affiliated with Shanghai Jiao Tong University School of Medicine, Professor Gang Liu's team from Beijing Children's Hospital affiliated with Capital Medical University, and Professor Haiyin Wang's team from Shanghai Municipal Health and Health Development Center was selected for an e-poster presentation. This study assessed the impact of the FilmArray Meningitis/Encephalitis Panel (FA-ME) on clinical outcomes and healthcare economics for pediatric patients.
2023 COMB丨Professor Peng Yuan: Precision Diagnosis and Treatment Strategies for Young Breast Cancer

2023 COMB丨Professor Peng Yuan: Precision Diagnosis and Treatment Strategies for Young Breast Cancer

The 6th Precision Oncology Summit and the 9th Individualized Breast Cancer Treatment Conference (2023 COMB) were held from December 23 to 26, 2023, in a hybrid online and offline format. Professor Yuan Peng from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered a lecture on "Precision Diagnosis and Treatment Strategies for Young Breast Cancer". After the conference, Oncology Frontier conducted an exclusive interview with Professor Yuan, where she shared her experiences related to the diagnosis and treatment of young breast cancer.
2023 COMB Conference | Professor Qiao Li : Current and Future Perspectives on Neoadjuvant Research for TNBC

2023 COMB Conference | Professor Qiao Li : Current and Future Perspectives on Neoadjuvant Research for TNBC

Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous subtype of breast cancer, accounting for 15% to 20% of all breast cancers. Compared to other subtypes, TNBC patients often experience rapid clinical progression, are diagnosed at a younger age, have faster distant recurrence, and more common visceral metastasis. Treatment for TNBC is usually limited to chemotherapy, resulting in a poorer prognosis. With the breakthroughs in immune checkpoint inhibitors in the field of oncology, TNBC, as a relatively "hot" subtype among the otherwise immune "cold" tumors, has become a focus of research, showing improved therapeutic effects. Furthermore, neoadjuvant treatment, as a pre-surgical intervention for breast cancer, which aims to "downstage and conserve the breast" and acts as "in vivo drug sensitivity testing," has also received considerable attention in recent years. At the 2023 COMB conference, Professor Qiao Li from the Cancer Hospital of the Chinese Academy of Medical Sciences reviewed the current state and future of TNBC neoadjuvant research. Subsequently, the "Oncology Frontier" magazine invited Professor Li to discuss the progress and future directions of TNBC neoadjuvant treatment.
Consensus on Targeted Prostate Biopsy at Panjiayuan by National Cancer Center

Consensus on Targeted Prostate Biopsy at Panjiayuan by National Cancer Center

In recent years, the incidence and mortality rates of prostate cancer in China have been rapidly increasing. Early diagnosis and treatment are crucial, with prostate biopsy histopathology being the gold standard for diagnosis. However, differences in equipment and technical levels among medical institutions in China pose challenges for prostate biopsies, including issues with technique selection and operational standards. On January 6, 2024, the "2024 Beijing Genitourinary Tumor Youth Forum" was successfully held in Beijing, jointly hosted by the Urology Male Reproductive Tumor Professional Committee of the Beijing Anti-Cancer Association and the Beijing Medical Awards Foundation. Professor Gang Song from the National Cancer Center/Chinese Academy of Medical Sciences Cancer Hospital's Department of Urology delivered a fascinating speech titled "Consensus on Targeted Prostate Biopsy at Panjiayuan by National Cancer Center (English)" and discussed the background, clinical significance, and challenges of the consensus in an interview with "Oncology Frontier."
VLA-4 Agonists – Enhancing Hematopoietic Stem Cell Engraftment, Accelerating Immune Reconstitution, and Increasing Treatment Success Rates for Patient

VLA-4 Agonists – Enhancing Hematopoietic Stem Cell Engraftment, Accelerating Immune Reconstitution, and Increasing Treatment Success Rates for Patient

Hematopoietic stem cell transplantation (HSCT) is an effective, and often the only, curative treatment for malignant hematological diseases such as leukemia. Key steps that impact the success of the transplantation include stem cell engraftment and the reconstitution of immune functions. From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was grandly held in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cell therapy, driving better clinical outcomes for patients with hematological diseases. At this conference, a team led by Professor Xianmin Song from Shanghai First People's Hospital presented an oral report titled "VLA-4 Agonists Promote Engraftment and Cellular Immune Reconstitution in Allogeneic Hematopoietic Stem Cell Transplantation," which garnered widespread attention. Professor Song was specially invited to our live interview room to share the main findings of his research and provide a detailed explanation of the latest developments in the critical steps of allogeneic stem cell transplantation: graft engraftment and immune reconstitution.
EBMT 2024 | Professor Qingxiao Song: PI3Kδ Inhibitors Show High Potential in the Treatment of cGVHD

EBMT 2024 | Professor Qingxiao Song: PI3Kδ Inhibitors Show High Potential in the Treatment of cGVHD

Chronic graft-versus-host disease (cGVHD) is a clinical syndrome occurring after allogeneic hematopoietic stem cell transplantation (allo-HSCT), where the recipient’s organs are attacked by donor-derived lymphocytes during the reconstitution of the donor's immune system. This includes both classic cGVHD and overlapping syndromes and is one of the main complications of transplantation, with an incidence rate of 30% to 70%. The mechanisms behind cGVHD are complex, its clinical manifestations diverse, and the individual differences significant. The course of the disease can be prolonged and persistent; if not properly diagnosed and treated, it can severely affect the patient's quality of life and long-term survival. With the introduction of guidelines, there are now standardized diagnostic criteria and first-line treatment protocols for cGVHD, but there is still no consensus on second-line treatments. PI3Kδ inhibitors, which interfere with the proliferation and survival of lymphocytes by inhibiting the activity of the PI3Kδ enzyme and thus suppress tumor growth, have not only introduced new drugs and strategies for non-Hodgkin's lymphoma but have also shown therapeutic potential in the treatment of GVHD. At the recent 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting, a basic study from the Second Affiliated Hospital of Army Medical University was selected for an oral presentation (Abstract No: OS7-05) [1], showcasing the activity of PI3Kδ inhibitors in the treatment of cGVHD. "Oncology Frontier - Hematology Frontier" has invited Professor Qingxiao Song from The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) to interpret and comment on this research for our readers.there is still no consensus on second-line treatments. PI3Kδ inhibitors, which interfere with the proliferation and survival of lymphocytes by inhibiting the activity of the PI3Kδ enzyme and thus suppress tumor growth, have not only introduced new drugs and strategies for non-Hodgkin's lymphoma but have also shown therapeutic potential in the treatment of GVHD. At the recent 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting, a basic study from the Second Affiliated Hospital of Army Medical University was selected for an oral presentation (Abstract No: OS7-05) [1], showcasing the activity of PI3Kδ inhibitors in the treatment of cGVHD. "Oncology Frontier - Hematology Frontier" has invited Professor Qingxiao Song from The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) to interpret and comment on this research for our readers.
Professor Pizzi Interprets the 2023 ESC Endocarditis Guidelines Update at ESCMID Global 2024

Professor Pizzi Interprets the 2023 ESC Endocarditis Guidelines Update at ESCMID Global 2024

Infective Endocarditis (IE) is a serious infectious cardiac condition. With advancements in medical technology, there have been significant changes in the diagnosis and treatment paradigms for IE. At the 34th European Congress of Clinical Microbiology & Infectious Diseases (ESCMID Global 2024), Infection Medicine Online had the privilege of interviewing Professor Maria Nazarena Pizzi from Vall d'Hebron University Hospital in Barcelona. Not only is Professor Pizzi a distinguished cardiologist, but she also participated in the update of the European Society of Cardiology (ESC) guidelines on endocarditis. In this interview, Professor Pizzi shared her expert insights on the updates to the 2023 ESC endocarditis guidelines, the application of imaging technologies, and the value of molecular diagnostic techniques
Definition and Diagnostic Criteria for Acute-on-Chronic Liver Failure: An Eastern Perspective

Definition and Diagnostic Criteria for Acute-on-Chronic Liver Failure: An Eastern Perspective

The "Acute-on-Chronic Liver Failure (ACLF) Monthly Review" is a scholarly column produced by the Chinese Acute-on-Chronic Liver Failure Consortium at the invitation of the editorial department of the journal Liver International. Each month, the column focuses on a specific area of ACLF to disseminate knowledge about the concept and significance of ACLF and to help readers stay updated on recent developments in the field. The aim is to benefit both liver disease specialists and researchers interested in field hotspots, as well as frontline clinical practitioners in need of practical knowledge.
 EBMT 2024 | Professor Linhua Yang: Embracing the Pulse of the Era, Focusing on the Advancements of Allogeneic Hematopoietic Stem Cell Transplantation and Cellular Immunotherapy in Hematologic Malignancies

 EBMT 2024 | Professor Linhua Yang: Embracing the Pulse of the Era, Focusing on the Advancements of Allogeneic Hematopoietic Stem Cell Transplantation and Cellular Immunotherapy in Hematologic Malignancies

From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was grandly held in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, pushing forward better clinical outcomes for patients with blood diseases and hematologic malignancies. In this issue, we are honored to have Professor Linhua Yang share selected advancements in the fields of allogeneic hematopoietic stem cell transplantation and cellular immunotherapy. We welcome our readers to engage and share their insights.
2023 COMB | Professor Fei Ma: The Knowns and Unknowns of Breast Cancer Immunotherapy

2023 COMB | Professor Fei Ma: The Knowns and Unknowns of Breast Cancer Immunotherapy

The 6th Precision Oncology Summit and the 9th Individualized Breast Cancer Treatment Conference (2023 COMB) took place from December 23 to 26, 2023, combining both online and offline formats. During the event, Professor Fei Ma from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered an insightful presentation titled "The Knowns and Unknowns of Breast Cancer Immunotherapy." Following his presentation, Oncology Frontier conducted an exclusive interview with Professor Ma to discuss the latest advancements in breast cancer immunotherapy.